Why Is ImmunityBio Stock Trading Higher Today - ImmunityBio (NASDAQ:IBRX)

ImmunityBio rises as route opens to broader Anktiva label

Shares in ImmunityBio shot up after it agreed a path with the FDA that should allow it to refile for wider use of its bladder cancer drug Anktiva.

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer

ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label expansion in bladder cancer, and investors are watching next steps on the planned data resubmission path. Trading volume reached 209.3 million shares, about 1,000% above its three-month average of 19.1 million shares. ImmunityBio IPO'd in 2015 and has…

ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's What Happened

ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Still a Buy?

ImmunityBio surge continues on sign its drug may be approved to treat a broader range of bladder cancers

Shares are up nearly 200% over the past six sessions....

Why Is ImmunityBio Stock Trading Higher Today - ImmunityBio (NASDAQ:IBRX)

ImmunityBio plans to resubmit its Anktiva FDA application after new feedback, sharing long-term data that shows high survival and bladder preservation in certain bladder cancer patients.

ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

New York, January 20, 2026, 12:42 ET — Regular session ImmunityBio, Inc. shares climbed roughly 24% to $6.82 by midday Tuesday after the company revealed the U.S. Food and Drug Administration provided guidance that could pave the way for a resubmission of its bladder cancer drug ANKTIVA. Earlier, the stock hit $7.97, fluctuating between $4.94 and $7.97 on about 159 million shares traded. (ImmunityBio) Why it matters now: this update puts a regul…